The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
In normal physiology, glucagon from pancreatic alpha cells plays an important role in
maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
Patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state,
and in response to ingestion of glucose or a mixed meal.glucagon, glucagon concentrations
fail to decrease appropriately and may even increase. This diabetic hyperglucagonaemia may
therefore contribute importantly to the hyperglycaemia of the patients.
Several glucose-lowering treatment modalities have been shown to affect glucagon levels in
patients with type 2 diabetes, but the role of glucagon in the glucose-lowering effects of
these treatment modalities has been difficult to discern. By using a glucagon receptor
antagonist (GRA) the investigators will exploit glucagon receptor antagonism to delineate the
role of glucagon during treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors and
dipeptidyl peptidase 4 (DPP-4) inhibitors, which have been shown to increase and decrease
plasma glucagon levels, respectively.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborator:
Eli Lilly and Company
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Empagliflozin Glucagon Glucagon-Like Peptide 1 Linagliptin